Neurocrine Biosciences (NBIX) Tops Q3 EPS by 75c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $143.29 --0%
EPS Growth %: -12.0%
Financial Fact:
General and administrative: 17.49M
Today's EPS Names:
RCBC, SSL, PFBC, More
EPS Growth %: -12.0%
Financial Fact:
General and administrative: 17.49M
Today's EPS Names:
RCBC, SSL, PFBC, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $0.97, $0.75 better than the analyst estimate of $0.22. Revenue for the quarter came in at $258.5 million versus the consensus estimate of $283.04 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercore ISI Upgrades ABB Ltd (ABB) to Outperform
- Customers Bancorp (CUBI) Tops Q3 EPS by 11c
- Flagstar Financial, Inc. (FLG) Misses Q3 EPS by 6c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
